Rivastigmine Actavis: Uses, Dosage & Side Effects
A cholinesterase inhibitor used to treat mild to moderately severe Alzheimer's disease dementia and dementia associated with Parkinson's disease
Rivastigmine Actavis contains the active substance rivastigmine, a dual cholinesterase inhibitor used to treat mild to moderately severe dementia caused by Alzheimer's disease and Parkinson's disease. In these conditions, certain nerve cells in the brain die, leading to reduced levels of the neurotransmitter acetylcholine. Rivastigmine works by blocking the enzymes acetylcholinesterase and butyrylcholinesterase that break down acetylcholine, thereby increasing its levels in the brain and helping to reduce cognitive and functional symptoms. Available as hard capsules in four strengths, Rivastigmine Actavis requires a prescription and is taken twice daily with food.
Quick Facts: Rivastigmine Actavis
Key Takeaways
- Rivastigmine Actavis is a dual cholinesterase inhibitor that blocks both acetylcholinesterase and butyrylcholinesterase, increasing acetylcholine levels in the brain to help manage cognitive decline in Alzheimer's disease and Parkinson's disease dementia.
- Treatment begins at a low dose of 1.5 mg twice daily and is gradually increased over several weeks to minimize gastrointestinal side effects; the maximum recommended dose is 6 mg twice daily.
- The most common side effects are nausea, vomiting, diarrhea, dizziness, and decreased appetite, which typically occur during dose escalation and often improve as the body adjusts to the medication.
- Rivastigmine Actavis should not be combined with metoclopramide or other cholinesterase inhibitors, and caution is required with beta-blockers and medications that affect heart rhythm (QT prolongation).
- If treatment is interrupted for more than three days, patients must consult their doctor before resuming, as the dose may need to be re-started from a lower level to prevent severe adverse effects.
What Is Rivastigmine Actavis and What Is It Used For?
Rivastigmine Actavis contains the active substance rivastigmine hydrogen tartrate, which belongs to a class of medications called cholinesterase inhibitors. This class of drugs is the cornerstone of symptomatic treatment for Alzheimer's disease and has been used globally for over two decades. Rivastigmine is unique among cholinesterase inhibitors because it inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), unlike donepezil and galantamine which primarily target AChE alone. This dual mechanism of action may provide additional therapeutic benefit, particularly as butyrylcholinesterase activity increases relative to acetylcholinesterase in the brains of patients with advancing Alzheimer's disease.
In patients with Alzheimer's disease dementia or dementia caused by Parkinson's disease, certain nerve cells in the brain degenerate and die. This neuronal loss is particularly prominent in areas responsible for memory, learning, and higher cognitive functions. One of the critical consequences of this neurodegeneration is a significant reduction in the neurotransmitter acetylcholine, a chemical messenger that enables nerve cells to communicate with one another. Acetylcholine plays a vital role in attention, memory formation, and other cognitive processes. The progressive loss of cholinergic neurons is strongly correlated with the severity of cognitive decline observed in these diseases.
Rivastigmine works by blocking the enzymes that break down acetylcholine in the brain. By inhibiting both acetylcholinesterase and butyrylcholinesterase, rivastigmine prevents the degradation of acetylcholine at cholinergic synapses, thereby increasing its concentration and prolonging its action at neuronal receptors. This enhanced cholinergic transmission can help improve or stabilize cognitive function, the ability to perform daily activities, and behavioral symptoms in affected patients. It is important to understand that rivastigmine does not cure Alzheimer's disease or Parkinson's disease dementia; rather, it treats the symptoms and may slow the rate of cognitive and functional decline.
Rivastigmine Actavis is specifically approved for two indications in adult patients:
- Mild to moderately severe Alzheimer's disease dementia: Alzheimer's disease is the most common cause of dementia worldwide, accounting for approximately 60–70% of all dementia cases according to the World Health Organization. It is a progressive neurodegenerative disorder characterized by a gradual decline in memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. The disease typically progresses over several years from mild forgetfulness to severe impairment of daily functioning. Rivastigmine has been shown in clinical trials to improve or stabilize cognition and global function in patients with mild to moderate Alzheimer's disease.
- Dementia associated with Parkinson's disease: Parkinson's disease is a neurodegenerative disorder primarily known for its motor symptoms (tremor, rigidity, bradykinesia), but cognitive impairment and dementia are common complications, particularly in later stages of the disease. Parkinson's disease dementia (PDD) affects an estimated 20–40% of patients with Parkinson's disease and is characterized by deficits in attention, executive function, visuospatial abilities, and memory. Rivastigmine is the only cholinesterase inhibitor specifically approved by the European Medicines Agency (EMA) for the treatment of PDD, based on evidence from the large randomized EXPRESS trial which demonstrated significant improvements in cognition and activities of daily living.
Unlike other cholinesterase inhibitors such as donepezil that target only acetylcholinesterase, rivastigmine also inhibits butyrylcholinesterase. Research has shown that butyrylcholinesterase activity increases in the brains of patients with Alzheimer's disease as the disease progresses, while acetylcholinesterase activity decreases. This dual inhibition may therefore become increasingly relevant in later stages of the disease, potentially offering a more sustained therapeutic benefit over time.
Rivastigmine Actavis is manufactured by Actavis Group (part of Teva Pharmaceutical Industries) and is a generic formulation of the original brand-name product. It is available in four capsule strengths: 1.5 mg, 3 mg, 4.5 mg, and 6 mg. Rivastigmine is also available as transdermal patches from other manufacturers, which may offer advantages in terms of gastrointestinal tolerability and ease of administration for patients who have difficulty swallowing capsules.
What Should You Know Before Taking Rivastigmine Actavis?
Contraindications
There are specific situations in which Rivastigmine Actavis must not be used. Understanding these absolute contraindications is essential before starting treatment.
- Hypersensitivity: Do not take Rivastigmine Actavis if you are allergic to rivastigmine, other carbamate derivatives, or any of the other ingredients in the capsules (magnesium stearate, colloidal silicon dioxide, hypromellose, microcrystalline cellulose, gelatin, titanium dioxide, iron oxides).
- Previous severe skin reaction to rivastigmine patch: If you have previously used a rivastigmine transdermal patch and experienced a skin reaction that spread beyond the patch area, or had an intense local reaction (such as blistering, increasing skin inflammation, or swelling) that did not improve within 48 hours of removing the patch, you should not take Rivastigmine Actavis capsules.
Warnings and Precautions
Before and during treatment with Rivastigmine Actavis, talk to your doctor if any of the following conditions apply to you, as closer monitoring may be necessary:
- Heart conditions: If you have or have ever had an irregular or slow heartbeat, QTc prolongation (a specific abnormality of the heart's electrical activity), a family history of QTc prolongation or torsades de pointes, or low blood levels of potassium or magnesium. Cholinesterase inhibitors can cause bradycardia (slow heart rate) through their vagotonic effects, and rivastigmine may exacerbate existing cardiac conduction abnormalities.
- Active peptic ulcer: Cholinesterase inhibitors increase gastric acid secretion through their pharmacological action. If you have or have ever had a stomach ulcer, you may be at increased risk of gastrointestinal bleeding. Your doctor will monitor you carefully.
- Urinary difficulties: If you have or have ever had problems with urination or urinary obstruction, rivastigmine may worsen these symptoms due to its cholinergic effects on bladder smooth muscle.
- Seizures: Cholinergic drugs have the potential to cause generalized seizures. While seizures may also be a manifestation of Alzheimer's disease itself, this risk should be considered when prescribing rivastigmine to patients with a history of seizure disorders.
- Asthma or respiratory disease: If you have asthma, chronic obstructive pulmonary disease (COPD), or other serious respiratory conditions, rivastigmine may increase bronchoconstriction and bronchial secretions due to its cholinergic activity, potentially worsening respiratory function.
- Kidney or liver impairment: Although rivastigmine is primarily metabolized by cholinesterase-mediated hydrolysis rather than hepatic cytochrome P450 enzymes, patients with significant kidney or liver disease may experience altered drug exposure. Your doctor may need to adjust monitoring accordingly.
- Low body weight: Patients weighing less than 50 kg may be at increased risk of adverse effects and may experience more weight loss during treatment. Regular weight monitoring is recommended.
- Tremor: Rivastigmine may worsen or cause extrapyramidal symptoms, including tremor. This is particularly relevant for patients with Parkinson's disease dementia.
If you have not taken Rivastigmine Actavis for more than three days, do not take the next dose until you have spoken with your doctor. Restarting at the previous dose after a gap of more than three days can cause severe gastrointestinal symptoms including intense nausea and vomiting. Your doctor will likely restart treatment at a lower dose and re-titrate gradually.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, seek advice from your doctor or pharmacist before taking this medicine. Given the typical age of onset of Alzheimer's disease, pregnancy is uncommon among patients taking rivastigmine, but it is important to be aware of the potential risks.
If you are pregnant, the potential benefit of taking Rivastigmine Actavis must be weighed against the possible effects on your unborn child. Rivastigmine Actavis should not be used during pregnancy unless absolutely necessary, as there are limited data on the use of rivastigmine in pregnant women. Animal studies have not indicated direct harmful effects on pregnancy or fetal development at therapeutic doses, but caution is warranted.
You should not breastfeed while taking Rivastigmine Actavis. In animal studies, rivastigmine was found to be excreted in breast milk, and a risk to the nursing infant cannot be excluded. If treatment with rivastigmine is essential, breastfeeding should be discontinued.
Driving and Operating Machinery
Your doctor will advise you whether your disease allows you to safely drive or operate machinery. Rivastigmine Actavis may cause dizziness and drowsiness, particularly at the start of treatment or when the dose is increased. If you feel dizzy or drowsy, do not drive, operate machinery, or perform any tasks that require alertness until these effects have resolved. Additionally, the underlying dementia itself may impair driving ability, and this should be assessed independently of medication effects.
How Does Rivastigmine Actavis Interact with Other Drugs?
Tell your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take. While rivastigmine is primarily metabolized by cholinesterase-mediated hydrolysis and has minimal interaction with the hepatic cytochrome P450 enzyme system, several clinically important drug interactions exist due to its cholinergic pharmacological activity. Understanding these interactions is crucial for safe and effective use of the medication.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Other cholinesterase inhibitors (donepezil, galantamine) | Additive cholinergic effects; increased risk of severe adverse reactions | Do not combine – use only one cholinesterase inhibitor at a time |
| Metoclopramide | Risk of extrapyramidal symptoms including joint stiffness, hand tremors, and involuntary movements | Avoid combination; use alternative antiemetics if needed |
| Beta-blockers (atenolol, metoprolol, propranolol) | Additive bradycardia (slow heart rate) which may lead to syncope (fainting) or loss of consciousness | Use with caution; monitor heart rate regularly; consider cardiology consultation |
| QT-prolonging drugs (certain antiarrhythmics, antipsychotics, antibiotics) | Potential additive effect on cardiac QT interval prolongation and risk of arrhythmias | Use with caution; ECG monitoring may be warranted |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Anticholinergic agents (oxybutynin, tolterodine, benztropine) | May counteract the cholinergic effects of rivastigmine, reducing its therapeutic benefit | Avoid if possible; review need for anticholinergic therapy |
| Succinylcholine-type muscle relaxants | Rivastigmine may prolong the neuromuscular blocking effects of depolarizing muscle relaxants during anesthesia | Inform anesthesiologist before any surgery; dose adjustments of relaxant may be needed |
| NSAIDs (ibuprofen, naproxen, aspirin) | Both rivastigmine (increased gastric acid) and NSAIDs increase risk of gastrointestinal ulceration and bleeding | Use with caution; consider gastroprotection with a proton pump inhibitor |
| Cholinergic agonists (bethanechol, pilocarpine) | Additive cholinergic stimulation; increased risk of cholinergic adverse effects | Use with caution; monitor for excessive cholinergic stimulation |
Before any surgical procedure, it is essential to tell your surgeon or anesthesiologist that you are taking Rivastigmine Actavis. The drug may exaggerate the effects of succinylcholine-type muscle relaxants used during general anesthesia, potentially leading to prolonged neuromuscular blockade and respiratory complications. Adequate planning and dose adjustment of the muscle relaxant can mitigate this risk.
It is also worth noting that rivastigmine has a low potential for drug interactions mediated through the cytochrome P450 enzyme system, as it is metabolized primarily by cholinesterase-mediated hydrolysis at the site of action. This means that unlike some other medications, rivastigmine is unlikely to significantly alter the blood levels of drugs metabolized by CYP enzymes such as CYP2D6, CYP3A4, or CYP1A2.
What Is the Correct Dosage of Rivastigmine Actavis?
Always take Rivastigmine Actavis exactly as your doctor has instructed. If you are unsure, consult your doctor, pharmacist, or nurse. The dose of rivastigmine is individualized based on each patient's response and tolerance to the medication. Slow, gradual dose titration is essential to minimize gastrointestinal side effects, which are the most common reason for treatment discontinuation.
Adults
Starting Dose
Dose: 1.5 mg twice daily (total 3 mg/day)
Duration: Minimum 2 weeks at this dose before increasing
Treatment is initiated at the lowest dose to allow the body to adjust. The capsules should be taken with food – once in the morning and once in the evening.
Dose Titration
Increments: Increase by 1.5 mg twice daily at intervals of at least 2 weeks
Titration schedule: 1.5 mg → 3 mg → 4.5 mg → 6 mg twice daily
Your doctor will assess your response and tolerability before each dose increase. If side effects such as nausea, vomiting, or diarrhea are troublesome, the dose increase may be delayed or the dose may be temporarily reduced.
Maintenance Dose
Effective therapeutic dose: 3 mg to 6 mg twice daily
Maximum dose: 6 mg twice daily (total 12 mg/day)
Your doctor will regularly evaluate whether the treatment is having the desired effect on cognitive function and daily activities. Regular weight monitoring is also recommended during treatment.
Children
Rivastigmine Actavis is not indicated for use in children or adolescents. There is no relevant use of rivastigmine in the pediatric population for the treatment of Alzheimer's disease or Parkinson's disease dementia, as these are conditions that primarily affect older adults.
Elderly Patients
Most patients taking rivastigmine are elderly. No specific dose adjustment is required based on age alone. However, elderly patients may be more susceptible to adverse effects, particularly gastrointestinal symptoms and weight loss. Careful dose titration and regular monitoring are essential. Patients with low body weight (under 50 kg) may experience adverse effects more frequently and may require slower titration or lower maintenance doses.
How to Take Rivastigmine Actavis
- Take the capsules twice daily: once in the morning and once in the evening.
- Always take the capsules with food to improve absorption and reduce gastrointestinal side effects.
- Swallow the capsules whole with liquid. Do not open, crush, or chew the capsules.
- Tell your caregiver that you are taking Rivastigmine Actavis, as they may need to help remind you to take your doses.
- Take the medication every day for it to be effective. Do not skip doses.
Missed Dose
If you forget to take a dose, simply wait until your next scheduled dose and take it at the usual time. Do not take a double dose to compensate for a forgotten dose. If you have not taken Rivastigmine Actavis for more than three consecutive days, you must contact your doctor before taking the next dose. Restarting at the previous dose after an extended interruption can cause severe gastrointestinal symptoms. Your doctor will typically restart treatment from the lowest dose (1.5 mg twice daily) and gradually re-titrate upward.
Overdose
If you accidentally take more Rivastigmine Actavis than prescribed, contact your doctor immediately. You may need urgent medical attention. Symptoms of overdose may include nausea, vomiting, diarrhea, high blood pressure, hallucinations, and cholinergic crisis with extreme muscle weakness. Severe cases may involve slow heart rate (bradycardia) and fainting (syncope). There is no specific antidote for rivastigmine overdose; treatment is supportive and symptomatic. Atropine may be used as an initial antidote in cases of severe cholinergic toxicity.
What Are the Side Effects of Rivastigmine Actavis?
Like all medicines, Rivastigmine Actavis can cause side effects, although not everybody gets them. Side effects are most likely to occur when you start treatment or when your dose is increased. In most cases, side effects gradually diminish as your body adjusts to the medication. Your doctor should monitor you regularly throughout treatment and will adjust the dose if side effects become troublesome.
Very Common
- Dizziness
- Decreased appetite
- Nausea
- Vomiting
- Diarrhea
Common
- Anxiety and agitation
- Excessive sweating
- Headache
- Heartburn (dyspepsia)
- Weight loss
- Abdominal pain
- Feeling of restlessness or confusion
- Fatigue or weakness
- General feeling of being unwell (malaise)
- Trembling (tremor)
- Drowsiness (somnolence)
- Nightmares
Uncommon
- Depression
- Difficulty sleeping (insomnia)
- Fainting (syncope) and accidental falls
- Elevated liver function tests
Rare and Very Rare
- Chest pain (angina pectoris)
- Skin rash and itching (pruritus)
- Seizures (convulsions)
- Gastric and duodenal ulcers
- High blood pressure (hypertension)
- Urinary tract infection
- Hallucinations (seeing things that are not real)
- Cardiac rhythm disturbances (both fast and slow heart rate)
- Gastrointestinal bleeding (blood in stool or vomit)
- Pancreatitis (severe upper abdominal pain with nausea and vomiting)
- Worsening of Parkinson's disease symptoms (muscle rigidity, difficulty moving)
- Severe vomiting potentially causing esophageal rupture
- Dehydration (from excessive fluid loss)
- Liver disorders (jaundice, dark urine, unexplained fatigue and loss of appetite)
- Aggression and restlessness
- Irregular heart rhythm
- Pisa syndrome (involuntary lateral bending of the trunk and head)
Additional Side Effects in Patients with Parkinson's Disease Dementia
Patients with dementia associated with Parkinson's disease may experience certain side effects more frequently or may develop additional adverse effects not commonly seen in Alzheimer's disease patients. These include:
- Very common: Tremor (worsening of existing tremor), accidental falls
- Common: Anxiety, restlessness, slow and fast heart rate, sleep disturbances, excessive salivation, dehydration, abnormally slow or uncontrollable movements (dyskinesia), worsening of Parkinsonian symptoms (rigidity, difficulty moving, muscle weakness), hallucinations, depression, high blood pressure
- Uncommon: Irregular heart rhythm, poor movement control, low blood pressure
Contact your doctor immediately if you experience severe or persistent vomiting, signs of dehydration (dry mouth, decreased urination, dark urine), chest pain, seizures, signs of liver problems (yellowing of skin or eyes, very dark urine), or severe abdominal pain. These may indicate serious complications that require prompt medical attention.
How Should You Store Rivastigmine Actavis?
Proper storage of medications is essential to maintain their effectiveness and safety. Rivastigmine Actavis should be stored in a cool, dry place at a temperature not exceeding 25°C (77°F). Do not store the capsules in the bathroom or near a sink, as humidity can damage the medication. Keep the capsules in their original blister packaging until you are ready to take them, as this protects them from moisture and light.
Keep Rivastigmine Actavis out of the sight and reach of children. Accidental ingestion of rivastigmine by a child can cause serious adverse effects including cholinergic crisis, which can be life-threatening. If a child accidentally swallows rivastigmine capsules, seek emergency medical attention immediately.
Do not use Rivastigmine Actavis after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of the stated month. Using expired medication may result in reduced effectiveness or potential harm.
Do not dispose of medications in household waste or drain them into wastewater. Return any unused or expired capsules to your pharmacist for proper disposal. These measures help protect the environment from pharmaceutical contamination.
What Does Rivastigmine Actavis Contain?
Each Rivastigmine Actavis capsule contains rivastigmine in the form of rivastigmine hydrogen tartrate as the active substance. The capsules are available in four strengths, each containing a different amount of rivastigmine:
| Strength | Capsule Color | Contents |
|---|---|---|
| 1.5 mg | Yellow cap and yellow body | Off-white to slightly yellowish powder |
| 3 mg | Orange cap and orange body | Off-white to slightly yellowish powder |
| 4.5 mg | Red cap and red body | Off-white to slightly yellowish powder |
| 6 mg | Red cap and orange body | Off-white to slightly yellowish powder |
The other (inactive) ingredients are:
- Capsule contents: Magnesium stearate, colloidal silicon dioxide (colloidal anhydrous silica), hypromellose, and microcrystalline cellulose. These excipients serve as fillers, binders, and flow agents to ensure uniform capsule content and consistent drug release.
- Capsule shell: Gelatin (the main structural component), titanium dioxide (E171, white colorant), and iron oxides (E172, yellow and/or red colorants depending on the strength). The different color combinations help distinguish between the four available strengths, reducing the risk of dosing errors.
Rivastigmine Actavis capsules are available in blister packs of 28, 56, or 112 capsules, as well as bottles containing 250 capsules. Not all pack sizes may be available in every country. The capsules should be stored in their original packaging until use.
Frequently Asked Questions
Rivastigmine Actavis is a dual cholinesterase inhibitor, meaning it blocks both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). This distinguishes it from donepezil (Aricept) and galantamine (Reminyl), which primarily inhibit AChE alone. The clinical significance of this dual inhibition is that butyrylcholinesterase becomes increasingly important in the brain as Alzheimer's disease progresses. Memantine, another Alzheimer's medication, works through a completely different mechanism (NMDA receptor antagonism) and is typically used in moderate to severe disease, sometimes in combination with a cholinesterase inhibitor. Your doctor will recommend the most appropriate medication based on your specific situation.
Yes, rivastigmine can be used in combination with memantine. These two medications work through different mechanisms – rivastigmine increases acetylcholine levels while memantine modulates glutamate activity – and combination therapy is commonly used in clinical practice for patients with moderate to severe Alzheimer's disease. Several clinical studies have suggested that combination therapy may provide additional benefits in terms of cognition, function, and behavior compared to either drug alone. Your doctor will determine whether combination therapy is appropriate for your specific case.
The effects of rivastigmine develop gradually over several weeks. Because treatment starts at a low dose and is slowly increased, it typically takes 12 to 26 weeks (3 to 6 months) to reach the therapeutic dose and assess the full effect of treatment. Some patients or their caregivers may notice subtle improvements in attention, alertness, or daily functioning within the first few weeks, but meaningful clinical benefit usually becomes apparent after reaching and maintaining the optimal dose for several weeks. Your doctor will regularly evaluate whether the medication is having its intended effect.
Caregivers play a crucial role in ensuring safe and effective treatment with rivastigmine. Key points for caregivers include: ensure the medication is taken twice daily with food at consistent times; monitor for side effects such as nausea, vomiting, weight loss, or excessive drowsiness; keep track of missed doses and contact the doctor if more than three days are missed; observe for any changes in behavior, mood, or cognitive function; ensure the patient attends regular doctor appointments for monitoring; and keep the medication securely stored away from children. Caregivers should also be aware that the medication does not stop the progression of dementia but may help maintain function for longer.
Both contain the same active ingredient (rivastigmine), but they are different formulations with distinct characteristics. Rivastigmine Actavis is an oral capsule taken twice daily, while the rivastigmine patch (transdermal formulation) is applied to the skin once daily. The patch provides more steady drug levels throughout the day and is generally associated with fewer gastrointestinal side effects (less nausea and vomiting) compared to capsules. However, the patch can cause skin reactions at the application site. Your doctor can help you decide which formulation is most appropriate based on your needs, preferences, and tolerance.
No, Rivastigmine Actavis is not used to prevent Alzheimer's disease and has not been shown to have preventive effects. It is a symptomatic treatment intended only for patients who have already been diagnosed with mild to moderately severe Alzheimer's disease dementia or Parkinson's disease dementia. Current research is ongoing into disease-modifying treatments and preventive strategies for Alzheimer's disease, but cholinesterase inhibitors like rivastigmine remain symptomatic treatments that address the cholinergic deficit rather than the underlying disease pathology.
References
- European Medicines Agency (EMA). Rivastigmine – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2015;(4):CD001191. doi:10.1002/14651858.CD001191.pub4
- National Institute for Health and Care Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Technology Appraisal Guidance [TA217]. Updated 2023. Available at: www.nice.org.uk/guidance/ta217
- Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine. 2004;351(24):2509-2518. doi:10.1056/NEJMoa041470
- World Health Organization (WHO). Dementia Fact Sheet. 2023. Available at: www.who.int
- American Academy of Neurology (AAN). Practice Parameter: Management of Dementia (an evidence-based review). Updated 2024.
- Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for Alzheimer's disease and Parkinson's disease dementia. Annals of the New York Academy of Sciences. 2010;1199:167-174.
- U.S. Food and Drug Administration (FDA). Exelon (rivastigmine tartrate) – Prescribing Information. Reference ID: 4756254.
Editorial Team
This article has been written and reviewed by medical professionals to ensure clinical accuracy and adherence to current evidence-based guidelines.
Medical Content
iMedic Medical Editorial Team – Specialists in Neurology, Geriatric Medicine, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, FDA, and NICE guidelines
Evidence Standard
Level 1A – Systematic reviews and meta-analyses of randomized controlled trials (GRADE framework)
Last Review
February 6, 2026 – Next scheduled review within 12 months
Conflict of Interest Declaration: The iMedic editorial team has no financial relationships with pharmaceutical companies. All content is independently produced without commercial sponsorship or advertising influence. Our editorial standards are published at iMedic Editorial Standards.